Tyche Wealth Partners Trims Stake in Eli Lilly

Hedge fund reduces holdings in pharmaceutical giant by over 39%

Apr. 18, 2026 at 9:56am

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate, heavy machinery and components that make up the industrial infrastructure of a major pharmaceutical manufacturer, conveying a sense of scale, complexity, and institutional strength without any text or identifiable branding.An inside look at the industrial machinery powering Eli Lilly's pharmaceutical production, reflecting the company's institutional might and financial stability.Indianapolis Today

Tyche Wealth Partners LLC, a financial management firm, decreased its position in Eli Lilly and Company (NYSE: LLY) by 39.4% during the fourth quarter, according to a recent SEC filing. The fund sold 2,015 shares, leaving it with 3,101 shares of the pharmaceutical company's stock valued at $3.3 million.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for blockbuster drugs like Trulicity and Mounjaro. Tracking institutional investor activity in the stock can provide insights into market sentiment and future performance.

The details

According to the SEC filing, Tyche Wealth Partners sold 2,015 shares of Eli Lilly stock during the fourth quarter of 2025. This reduced the fund's total holdings in the company to 3,101 shares, worth approximately $3.3 million. The move comes as Eli Lilly's stock has seen significant volatility in recent months amid regulatory changes and competitive pressures in the diabetes medication market.

  • Tyche Wealth Partners filed the 13F report disclosing the stake reduction on April 18, 2026.
  • The trades occurred during the fourth quarter of 2025.

The players

Tyche Wealth Partners LLC

A financial management firm that decreased its position in Eli Lilly and Company by 39.4% in Q4 2025.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for developing and commercializing a range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the ongoing shifts in institutional ownership of Eli Lilly stock as the company navigates a dynamic pharmaceutical landscape. Investors will likely continue to monitor Lilly's performance and any further changes in major shareholders' positions.